Table of Contents
- What This Post Covers
- What Is Serum Cortisol And Why Does It Matter
- How Ashwagandha Is Thought To Influence Cortisol
- The Key Ashwagandha Cortisol Serum Studies Explained
- KSM-66 Cortisol Serum Results And What Makes It Different
- Ashwagandha Cortisol Reduction Percentage Across Studies
- Dosage Signals From The Clinical Trials
- How Long Before You See Results
- What Else Improves Alongside Cortisol
- Are The Results Consistent Across Studies
- Safety Considerations And Drug Interactions
- Frequently Asked Questions
- Bottom Line Summary
What This Post Covers
If you have searched for hard numbers on the ashwagandha and cortisol serum study results landscape, you have probably noticed two problems. First, the same vague bullet points get recycled endlessly across health websites without citing actual study parameters. Second, many posts conflate perceived stress questionnaire scores with measured blood biomarkers, which are fundamentally different types of evidence.
This post focuses specifically on ashwagandha cortisol blood levels as measured in serum — meaning a blood draw, processed in a laboratory, and reported in nanomoles per liter or micrograms per deciliter. That is a harder, more objective endpoint than a self-reported stress scale, and it is the data most readers are actually trying to find when they search this topic.
We will walk through the landmark randomized controlled trials, explain the specific ashwagandha cortisol reduction percentage figures you may have seen cited, break down what KSM-66 data shows specifically, and address the practical questions around dose and timeline.
No supplement hype. Just the numbers, the study designs, and what the limitations mean for you as a reader trying to make an informed decision.
What Is Serum Cortisol And Why Does It Matter
Cortisol is a glucocorticoid hormone produced by the adrenal cortex in response to signals from the hypothalamic-pituitary-adrenal (HPA) axis. In short bursts, elevated cortisol is adaptive — it mobilizes energy, sharpens focus, and prepares the body to respond to a perceived threat. This is the classic fight-or-flight response working exactly as designed.
The problem emerges when cortisol stays chronically elevated. In modern adults dealing with sustained psychological stress — work pressure, financial strain, relationship difficulties, sleep deprivation — cortisol output can remain persistently high over days, weeks, and months. Chronically elevated cortisol is associated with:
- Disrupted sleep architecture, particularly reduced deep sleep and frequent nighttime waking
- Impaired immune regulation
- Elevated fasting blood glucose and insulin resistance over time
- Weight gain, particularly around the abdomen
- Anxiety, irritability, and difficulty with emotional regulation
- Suppression of thyroid hormone conversion
- Reduced testosterone in men
Why serum measurement matters specifically: When researchers measure the ashwagandha cortisol measure in a clinical trial, they are drawing blood and measuring the actual circulating hormone. This is distinct from salivary cortisol, which reflects free (unbound) cortisol, or urinary cortisol, which captures a 24-hour output average. Serum cortisol captures total cortisol — both protein-bound and free fractions — and is the most commonly used clinical endpoint in RCTs examining the ashwagandha cortisol response.
For serum cortisol, a morning reading (approximately 8 AM) in healthy adults typically falls between 10 and 20 micrograms per deciliter (µg/dL), or roughly 280–550 nmol/L. Values consistently above this range, particularly in individuals reporting chronic stress, signal dysregulation of the HPA axis.
This context matters because when you see a study reporting a statistically significant reduction in serum cortisol after ashwagandha supplementation, you need to understand what baseline those participants started from, what the absolute change was in those units, and whether the post-intervention levels landed in a more physiologically normal range.
How Ashwagandha Is Thought To Influence Cortisol
Withania somnifera, commonly known as ashwagandha or Indian ginseng, is classified as an adaptogen — a category of botanical compounds thought to help the body maintain homeostasis under stress. The proposed mechanisms through which withania somnifera cortisol serum levels may be reduced are reasonably well characterized at this point, though not yet fully elucidated.
Primary proposed mechanisms include:
1. HPA Axis Modulation The withanolides — the primary bioactive steroidal lactones in ashwagandha root — are thought to modulate the sensitivity and reactivity of the HPA axis. By dampening the hypothalamic and pituitary components of the stress response cascade, ashwagandha may reduce the signal that drives adrenal cortisol output in the first place, rather than simply interfering with cortisol downstream.
2. GABAergic Activity Several withanolides have demonstrated affinity for GABA-A receptors in preclinical studies. Because GABA is the primary inhibitory neurotransmitter in the central nervous system, increased GABAergic signaling tends to reduce overall neurological arousal — which feeds back to reduce HPA axis activation.
3. Anti-inflammatory Pathway Modulation Chronic stress and elevated cortisol create a feedback loop with inflammatory cytokines. Ashwagandha has demonstrated anti-inflammatory properties in multiple in vitro and animal studies, and some researchers propose that reducing inflammatory signaling may help normalize cortisol regulation over time.
4. Direct Withanolide Activity Some withanolides have structural similarities to steroid hormones and may interact with glucocorticoid receptors directly, though this mechanism is less established in human trials.
What is important to understand is that ashwagandha appears to work over time through cumulative adaptation rather than acute suppression. This is consistent with the clinical trial timelines — most studies showing significant ashwagandha cortisol improvement in serum measurements ran for 60 days or more, not days or weeks.
Support Your Stress Response, Lower Cortisol and Feel Calmer, Clearer and More Like Yourself Again.
Try our new organic cortisol balance drops risk free
Shop Organic Cortisol Balance Drops
The Key Ashwagandha Cortisol Serum Studies Explained
Let us look at the actual clinical evidence from the most-cited ashwagandha cortisol serum study trials, including study design, sample size, intervention, and the reported serum cortisol outcomes.
Study 1: The 64-Adult Chronic Stress RCT (2019)
Published: 2019 Study Type: Randomized, double-blind, placebo-controlled trial Sample Size: 64 adults with chronic stress Source: PMC6979308 (NCBI PubMed Central)
This is arguably the most frequently cited ashwagandha cortisol serum study in circulation, and for good reason — its design is rigorous and its endpoints are clearly defined.
Participants: Adults aged 18 to 54 who met screening criteria for chronic stress based on validated questionnaire scores. Participants were excluded if they had serious medical conditions, were taking medications that could influence cortisol, or were pregnant.
Intervention: Participants received ashwagandha root extract at a standardized dose over the intervention period. The control group received a matched placebo.
Primary Outcomes: Serum cortisol levels measured at baseline and at endpoint, alongside validated psychological questionnaire scores for stress, anxiety, and sleep quality.
Results on Serum Cortisol: The ashwagandha group demonstrated a statistically significant reduction in serum cortisol compared to the placebo group. The between-group difference was significant at the p < 0.05 threshold, and the ashwagandha group's cortisol levels at endpoint were meaningfully lower than their own baseline values — not simply lower than placebo by a marginal amount.
Accompanying Outcomes: Alongside the ashwagandha cortisol blood levels improvement, the trial also reported significant improvements in:
- Perceived stress scores (PSS)
- Anxiety scores
- General wellbeing ratings
- Sleep quality measures
This pattern — where serum cortisol reductions co-occur with subjective stress improvements — is consistent across the literature and supports the biological plausibility of the observed cortisol changes rather than suggesting they are measurement artifacts.
Study 2: The 23% Cortisol Reduction Trial (2019)
Published: 2019 Study Type: Randomized trial Source: PMC6750292 (NCBI PubMed Central)
This is the trial behind the ashwagandha 14% cortisol reduction figure that circulates widely — though it is important to clarify that this specific trial actually reported a 23% reduction in morning cortisol versus placebo, which is the more accurate figure for this study.
The 23% figure explained: The ashwagandha supplementation group showed morning serum cortisol levels that were approximately 23% lower compared to the placebo group at study endpoint. Morning cortisol is significant because it represents the cortisol awakening response — the natural cortisol spike that occurs within 30 to 45 minutes of waking, which is one of the most sensitive indicators of HPA axis activity.
DHEA-S Finding: The same study also reported a 23% reduction in DHEA-S (dehydroepiandrosterone sulfate) in this study context. DHEA-S is often used as a marker of adrenal output more broadly, and its reduction alongside cortisol suggests the effect is not simply cortisol-specific but may reflect broader HPA axis regulation.
What this means practically: A 23% reduction in morning cortisol is a clinically meaningful change. If a chronically stressed individual starts with a morning cortisol of, say, 22 µg/dL — modestly above the normal range — a 23% reduction would bring them to approximately 17 µg/dL, squarely within normal parameters. This is not a trivial effect size.
Study 3: The 240 mg/Day, 60-Day Trial
Published: Referenced in Columbia University health summaries Dose: 240 mg/day Duration: 60 days
This trial examined a lower end dose — 240 mg per day for 60 days — and still found significant reductions in serum cortisol alongside improvements in sleep quality and anxiety scores.
The 60-day timeline here is an important data point. It suggests that the cortisol-reducing effects of ashwagandha are cumulative rather than immediate. Participants who completed the full 60-day protocol showed meaningful changes; shorter durations in other studies tend to show weaker or non-significant effects on blood biomarkers.
This trial also adds to the growing evidence that even doses below the 300–600 mg threshold discussed in NIH ODS guidance can produce measurable ashwagandha cortisol improvement in serum, particularly when sustained over sufficient duration.
KSM-66 Cortisol Serum Results And What Makes It Different
When people search for KSM-66 cortisol serum results or KSM-66 cortisol data, they are asking about a specific proprietary extract of ashwagandha root — and the distinction matters because supplement quality and standardization vary enormously across products.
What is KSM-66? KSM-66 is a full-spectrum ashwagandha root extract manufactured by Ixoreal Biomed. It is standardized to a minimum of 5% withanolides and is produced using a proprietary extraction process without alcohol solvents. The "full-spectrum" designation means the extract aims to preserve the ratio of bioactive constituents as they appear in the natural root, rather than isolating a single compound.
Why standardization matters for cortisol research: When you read a study reporting a significant reduction in ashwagandha cortisol blood levels, that result is only replicable if the supplement used in the study contains a consistent, verified amount of the active compounds. Unstandardized ashwagandha powders or low-quality extracts may contain dramatically different withanolide concentrations from batch to batch, making replication of research outcomes in the consumer context difficult.
KSM-66 Cortisol Data From Clinical Trials: Several of the most rigorous RCTs examining KSM-66 cortisol data have used this extract specifically, which is part of why KSM-66 is often recommended as the benchmark form when discussing research-backed supplementation. The KSM-66 cortisol serum results from trials generally align with the broader ashwagandha cortisol literature — showing statistically significant reductions in serum cortisol at doses of 300–600 mg/day over 60+ day periods.
The reproducibility of results with KSM-66 across multiple independent research teams is stronger than for generic ashwagandha root powder, making it the most evidence-supported extract form for anyone specifically interested in the serum cortisol endpoint.
Other Standardized Extracts: Sensoril is another commonly referenced standardized ashwagandha extract, though it is derived from both root and leaf material (KSM-66 is root-only). Some clinical trials on the withania somnifera cortisol serum endpoint have used Sensoril rather than KSM-66, and results are generally consistent, though dose comparisons require adjustment because the extraction ratios differ.
Support Your Stress Response, Lower Cortisol and Feel Calmer, Clearer and More Like Yourself Again.
Try our new organic cortisol balance drops risk free
Shop Organic Cortisol Balance DropsAshwagandha Cortisol Reduction Percentage Across Studies
This section pulls together the ashwagandha cortisol reduction percentage data across the trials discussed, because this is one of the most common data points people are looking for when they research the ashwagandha cortisol serum study literature.
| Study Parameters | Dose | Duration | Cortisol Reduction vs. Placebo | |---|---|---|---| | 64-adult chronic stress RCT (PMC6979308) | Standardized root extract | 60 days | Statistically significant reduction (p < 0.05) | | Morning cortisol RCT (PMC6750292) | Standardized root extract | Study period | ~23% reduction in morning serum cortisol | | 240 mg/day trial | 240 mg/day | 60 days | Significant serum cortisol reduction | | NIH ODS-reviewed studies | 500–600 mg/day | Variable | Consistent cortisol reductions reported |
On the "14%" figure: The ashwagandha 14% cortisol reduction figure that appears frequently in online health content appears to be derived from older or differently powered studies, or may represent an average across a pooled analysis rather than a single trial result. The 23% figure from the 2019 PMC6750292 trial represents one of the more precisely reported numbers in the current literature for morning serum cortisol specifically.
Why percentages vary across studies: The range of reported ashwagandha cortisol reduction percentage figures — from roughly 14% to 30% depending on the study — reflects several legitimate sources of variation:
- Baseline cortisol levels of participants: People who start with higher cortisol tend to show larger absolute and relative reductions.
- Time of blood draw: Morning cortisol awakening response versus afternoon or random cortisol will show different baselines and different effect sizes.
- Extract type and standardization: KSM-66 studies may show different percentage outcomes than generic extract studies.
- Dose: Higher doses (600 mg/day) tend to produce more robust cortisol effects than lower doses (240 mg/day), though both produce statistically significant results.
- Study duration: 8-week studies tend to show stronger effects than 4-week studies for the serum cortisol endpoint.
The takeaway is not that one percentage is "correct" and others are wrong, but rather that the ashwagandha cortisol response is dose-dependent, duration-dependent, and population-dependent — which is true of essentially every pharmacologically active compound, botanical or pharmaceutical.
Dosage Signals From The Clinical Trials
The dosage question is one of the most practically important aspects of interpreting ashwagandha cortisol serum study data, because the dose used in a study directly determines whether that study's results are relevant to whatever product a consumer might actually purchase.
What the research shows on dose:
240 mg/day: This lower dose, used in at least one 60-day trial, produced significant reductions in serum cortisol and improvements in sleep and anxiety. This is encouraging because it suggests threshold effects are achievable below the commonly cited 300–600 mg range.
300–600 mg/day: This is the range most consistently associated with statistically significant ashwagandha cortisol blood levels reductions in the clinical literature. The NIH Office of Dietary Supplements (ODS) notes that studies showing the strongest effects on stress, anxiety, sleep, and serum cortisol tended to use doses in the 500–600 mg/day range.
The WFSBP/CANMAT Recommendation: The World Federation of Societies of Biological Psychiatry and the Canadian Network for Mood and Anxiety Treatments provisionally recommended 300 to 600 mg/day of standardized ashwagandha root extract for generalized anxiety disorder based on the available evidence base. While this recommendation was specifically for anxiety rather than serum cortisol normalization, the dose signal is consistent across both endpoints.
Practical Dose Considerations:
- Most commercial KSM-66 products provide either 300 mg once daily or 300 mg twice daily (600 mg total)
- The research does not currently support that going higher than 600 mg/day produces proportionally greater cortisol reduction — and higher doses may increase the risk of the gastrointestinal side effects discussed in the safety section
- Taking the dose in the evening may have additional benefit for sleep-related cortisol normalization, though morning dosing has also been used successfully in trials
- Splitting doses (300 mg morning, 300 mg evening) is a common approach that several trials have used with good outcomes
How Long Before You See Results
The timeline question is consistently one of the most searched aspects of ashwagandha cortisol improvement research, and the clinical data gives us reasonably clear guidance.
4 Weeks: Some studies show early signals of reduced perceived stress at 4 weeks, but changes in actual ashwagandha cortisol blood levels at this interval tend to be smaller and less consistently statistically significant than at 8 weeks.
8 Weeks (60 Days): This is the intervention duration most consistently associated with statistically significant serum cortisol reductions across multiple independent trials. Both the 64-adult chronic stress RCT and the 240 mg/day trial used approximately 60-day protocols and showed robust cortisol outcomes. For the purposes of using ashwagandha cortisol measure data to set realistic expectations, 60 days appears to be the minimum meaningful trial duration.
12 Weeks: Some trials extend to 12 weeks and show that benefits either maintain or continue to strengthen beyond the 8-week mark. There is no strong evidence from the available data that benefits plateau and then reverse during continued supplementation within this timeframe.
Why It Takes This Long: The time-dependent nature of the cortisol response makes biological sense given the proposed mechanisms. Modulating HPA axis sensitivity and reactivity is not an acute effect — it reflects gradual neuroadaptation. The GABA receptor interactions and the downstream effects on hypothalamic corticotropin-releasing hormone (CRH) signaling take weeks to produce measurable changes in output hormones like cortisol.
This is meaningfully different from, say, a stimulant that produces acute cortisol changes within hours. The adaptogenic mechanism is slower, but it works on the regulatory system rather than simply suppressing or stimulating output acutely.
What This Means For Consumer Expectations: If someone tries ashwagandha for two weeks and does not notice a difference, this does not mean the intervention is not working. The clinical evidence suggests the relevant timeline for serum cortisol changes is 8 weeks of consistent daily use. Setting expectations around this timeline is important for compliance — people who expect fast results may discontinue before the intervention has had time to produce measurable effects.
What Else Improves Alongside Cortisol
One of the stronger arguments for the biological validity of the serum cortisol changes reported in ashwagandha cortisol serum study trials is that multiple other outcomes improve simultaneously, and they improve in a pattern that is consistent with what we would expect if cortisol was genuinely being reduced.
Sleep Quality: Multiple trials report significant improvements in sleep quality, sleep onset latency, and nighttime awakening frequency alongside cortisol reductions. This is consistent with cortisol physiology — elevated evening cortisol is one of the primary biological drivers of insomnia and poor sleep quality, so if cortisol is genuinely declining, improved sleep is an expected co-outcome.
Anxiety: Anxiety scores on validated instruments (GAD-7, STAI, and similar scales) consistently improve in the ashwagandha arms of cortisol trials. The relationship between cortisol and anxiety is bidirectional and well-established, so this co-reduction is expected.
Perceived Stress: Psychological stress measures (most commonly the Perceived Stress Scale, or PSS) improve alongside serum cortisol reductions. While PSS scores are subjective, their co-movement with an objective biomarker like serum cortisol strengthens the case that both are reflecting a real underlying change in HPA axis activity.
Fatigue: The NIH ODS fact sheet specifically lists fatigue reduction as one of the consistently reported benefits in ashwagandha supplementation trials, alongside cortisol reduction. Chronic cortisol dysregulation contributes to fatigue through multiple pathways, including disrupted sleep and altered glucose metabolism, so this finding aligns with the mechanism.
DHEA-S: As noted in the 23% cortisol reduction study, DHEA-S also declined in the ashwagandha group. DHEA-S is produced by the adrenal cortex alongside cortisol, and its co-reduction suggests the effect may involve broader adrenal output modulation rather than cortisol-specific suppression.
What Does Not Appear To Change: It is worth noting that not all outcomes show consistent improvements across all trials. Effects on blood pressure, testosterone, body composition, and cognitive performance are more variable across studies and should not be assumed to accompany the cortisol improvements as reliably.
Are The Results Consistent Across Studies
This is a critical question for anyone trying to assess the evidentiary weight behind ashwagandha cortisol serum data. Consistency across independent trials is one of the key criteria for moving from "interesting finding" to "credible evidence."
The Short Answer: Yes, with important caveats.
What Is Consistent: The direction of the effect — ashwagandha supplementation reducing serum cortisol versus placebo — is highly consistent across the trials in the current literature. The NIH ODS fact sheet, which reviewed available evidence as of 2021 and noted that most studies published afterward also suggest beneficial impact on perceived stress, reflects a body of literature where the cortisol-reducing direction of effect is replicated across multiple independent research groups.
The clinical significance of the effect — meaning the reductions are large enough to move participants from elevated-to-normal cortisol ranges — also appears consistent in the trials that reported both absolute values and percent changes.
What Is Less Consistent: The exact magnitude of the ashwagandha cortisol reduction percentage varies by study, as discussed in detail above. This is not necessarily evidence of inconsistency in the intervention's efficacy — it more likely reflects the methodological variation (different doses, different populations, different blood draw timing, different extract forms) that exists across a body of literature produced by different research groups.
Limitations The Research Community Acknowledges: The NIH ODS fact sheet is candid about limitations: most ashwagandha trials are small (many under 100 participants), short-term (8–12 weeks), and use variable doses and extract types. This means the overall evidence is promising but not yet at the level of certainty we would have for a medication with hundreds of large-scale trials.
There is also a publication bias concern in the botanical supplement literature broadly — negative trials are less likely to be published, which means the published literature may over-represent positive findings. This is a systemic issue in supplement research that applies to ashwagandha as much as to any other botanical.
The Bottom Line on Consistency: The cortisol-reducing effect of ashwagandha is among the more consistently replicated findings in the adaptogen literature. It passes the basic threshold of independent replication by multiple research groups using different participant populations and study designs. It does not yet meet the evidentiary bar of pharmaceutical-level certainty, but it is meaningfully more than a single-study anomaly.
Safety Considerations And Drug Interactions
No review of ashwagandha cortisol serum study data is complete without an honest assessment of safety and potential interactions, because the decision to supplement should weigh both potential benefits and potential risks.
General Safety Profile: Ashwagandha is generally considered safe for most healthy adults at doses of 300–600 mg/day for periods up to 12 weeks. The adverse events reported in clinical trials are predominantly mild and gastrointestinal in nature — nausea, upset stomach, loose stools — and tend to resolve upon discontinuation.
Liver Safety Concern: The NIH ODS fact sheet notes that rare cases of liver injury have been reported in individuals taking ashwagandha supplements, including one case of acute liver failure. This is a rare event and causality has not been definitively established in all cases, but it is important information for anyone considering long-term use. Individuals with existing liver conditions or who consume significant alcohol should consult a physician before use.
Thyroid Interaction: Ashwagandha may increase thyroid hormone levels (T3 and T4), particularly in individuals with subclinical hypothyroidism. For people already taking thyroid medications (levothyroxine, for example), this interaction could result in thyroid levels moving out of the target range. Regular thyroid monitoring is advisable for individuals on thyroid medication who add ashwagandha.
Diabetes Medications: Ashwagandha has demonstrated blood glucose-lowering properties in some trials. In individuals taking insulin or oral hypoglycemic agents, this additive effect could theoretically cause hypoglycemia. Monitoring blood glucose is advisable when beginning ashwagandha supplementation if on diabetes medications.
Blood Pressure Medications: Some evidence suggests ashwagandha may have mild antihypertensive effects. Combining with antihypertensive medications requires monitoring to avoid additive blood pressure lowering.
Sedative Medications: Given its GABAergic activity and sleep-promoting properties, ashwagandha may have additive effects with benzodiazepines, non-benzodiazepine sleep aids (like zolpidem), or other CNS depressants. Caution is warranted.
Immunosuppressants: Ashwagandha has immunomodulatory properties. In individuals taking immunosuppressant medications (post-transplant patients, autoimmune disease patients), this interaction warrants discussion with a prescribing physician before use.
Pregnancy: Ashwagandha has historically been used in traditional medicine to induce labor and should be avoided during pregnancy. The NIH ODS lists this as a specific contraindication.
Who Should Consult A Doctor First: Anyone with thyroid disease, diabetes, hypertension, autoimmune conditions, liver disease, or who takes regular prescription medications should consult a healthcare provider before beginning ashwagandha supplementation.
Support Your Stress Response, Lower Cortisol and Feel Calmer, Clearer and More Like Yourself Again.
Try our new organic cortisol balance drops risk free
Shop Organic Cortisol Balance DropsFrequently Asked Questions
Does ashwagandha actually lower serum cortisol in humans, or is this just marketing?
The clinical trial data from multiple randomized, double-blind, placebo-controlled trials does show statistically significant reductions in serum cortisol in the ashwagandha groups versus placebo. This is not solely marketing language. However, the evidence base has limitations — trials are mostly small and short-term — so it represents credible preliminary-to-moderate evidence rather than pharmaceutical-level certainty.
What dose is used in the studies showing cortisol reduction?
The clinical trials showing significant ashwagandha cortisol blood levels reductions have used doses ranging from 240 mg/day at the lower end up to 600 mg/day at the higher end. The NIH ODS notes that 500–600 mg/day doses tend to produce stronger effects. The provisional WFSBP/CANMAT recommendation for anxiety is 300–600 mg/day of standardized root extract.
How long does it take to see cortisol changes?
Based on the clinical trial data, the most consistent and statistically significant serum cortisol reductions appear at the 8-week (60-day) mark. Some earlier subjective improvements may appear at 4 weeks, but blood biomarker changes take longer. Plan for a minimum 8-week consistent trial before evaluating results.
Is KSM-66 better than generic ashwagandha for cortisol reduction?
KSM-66 is a standardized, quality-controlled root extract with its own clinical trial data. It is more reliably consistent in withanolide content than unstandardized powders. The published KSM-66 cortisol data aligns with the broader ashwagandha cortisol literature. For research-backed supplementation, a standardized extract like KSM-66 or Sensoril is preferable to non-standardized root powder.
What is the 14% cortisol reduction figure from?
The ashwagandha 14% cortisol reduction figure that circulates online may represent findings from specific older studies or pooled analyses rather than the primary 2019 trials, which reported larger effects (approximately 23% reduction in morning cortisol in at least one trial). The exact figure varies by study because of differences in dose, extract type, timing of blood draws, and participant baseline characteristics.
Can ashwagandha help with chronic stress specifically?
Yes — the 64-adult RCT cited in this post specifically enrolled adults with chronic stress and showed significant reductions in both serum cortisol and psychological stress measures. Chronic stress populations appear to be a responsive demographic for the ashwagandha cortisol response, likely because they start with meaningfully elevated cortisol that has room to be normalized.
Is it safe to take ashwagandha long-term?
Most safety data exists for periods up to 12 weeks. Long-term safety data beyond 3 months is limited. Rare cases of liver injury have been reported. People with existing health conditions or medication regimens should consult a physician. Periodic breaks from supplementation are a reasonable precaution given the limited long-term data.
Does ashwagandha affect cortisol differently in men versus women?
The available trial data does not strongly support a sex-specific cortisol response, but most trials have not been powered to detect sex differences. The 2019 DHEA-S finding may have different implications for men and women given the different roles of adrenal androgens in the two sexes. This remains an area where more sex-stratified data would be valuable.
Will ashwagandha help with cortisol-related weight gain?
Some trials have reported modest improvements in body weight and body fat percentage, particularly in overweight or obese individuals with chronic stress. However, the direct link between ashwagandha-induced cortisol reductions and weight loss is not yet cleanly established in controlled research. Cortisol normalization alone is unlikely to produce dramatic weight changes without accompanying diet and lifestyle interventions.
Does the time of day I take ashwagandha matter for cortisol?
Trials have used various dosing schedules — once daily in the morning, once daily in the evening, and split twice-daily dosing. There is not yet enough direct comparison data to definitively say that one timing protocol produces larger serum cortisol reductions than another. Some practitioners prefer evening dosing to leverage the sleep-promoting effects alongside cortisol normalization.
Bottom Line Summary
The body of evidence on ashwagandha and cortisol serum study results is more rigorous than many botanicals enjoy, and more limited than a pharmaceutical intervention would typically accumulate. Here is what the data supports and what it does not:
What the data supports:
- Statistically significant reductions in serum cortisol in multiple randomized, double-blind, placebo-controlled trials
- Approximately 23% reduction in morning serum cortisol in at least one well-designed 2019 trial
- Consistent cortisol-reducing effects across multiple independent research groups
- Dose range of 300–600 mg/day of standardized root extract as the evidence-backed target
- 60-day minimum duration as the relevant window for serum biomarker changes
- Co-improvements in sleep quality, anxiety, perceived stress, and fatigue alongside cortisol normalization
- KSM-66 cortisol serum results specifically supported by multiple quality-controlled trials
What the data does not yet fully support:
- Long-term safety data beyond 12 weeks
- Definitive sex-stratified or age-stratified cortisol response data
- Clear comparison data between ashwagandha and other interventions for cortisol normalization
- Large-scale trials (most remain under 100 participants)
For the reader making a practical decision: If you are a healthy adult experiencing chronic stress with associated elevated cortisol — confirmed ideally by a blood test — and you are not on medications that interact with ashwagandha, the clinical data supports a reasonable basis for trying a standardized ashwagandha root extract (KSM-66 or Sensoril) at 300–600 mg/day for a minimum of 60 days, with a physician's awareness given the thyroid, glucose, and liver interaction signals discussed above.
This is not a replacement for addressing the root causes of chronic stress. It is a botanical intervention with credible, replicated clinical evidence behind a specific mechanism — HPA axis modulation and serum cortisol reduction — that is more substantiated than most claims in the supplement industry.
Support Your Stress Response, Lower Cortisol and Feel Calmer, Clearer and More Like Yourself Again.
Try our new organic cortisol balance drops risk free
Shop Organic Cortisol Balance DropsReferences and Sources:
- PMC6979308 — Randomized, double-blind, placebo-controlled trial in 64 adults with chronic stress (2019), NCBI PubMed Central
- PMC6750292 — Randomized trial reporting 23% morning cortisol reduction with ashwagandha supplementation (2019), NCBI PubMed Central
- NIH Office of Dietary Supplements — Ashwagandha Fact Sheet for Health Professionals (updated post-2021), ods.od.nih.gov
- Columbia University health summary — 240 mg/day, 60-day ashwagandha cortisol trial data
This blog post is intended for informational purposes only and does not constitute medical advice. Consult a qualified healthcare provider before beginning any new supplement regimen, particularly if you have existing health conditions or take prescription medications.
0 comments